Recursos
Cosopt Início Referencias
  1. Flammer J, Orgül S, Costa VP y cols. The impact of ocular blood flow in glaucoma. Prog Ret Eye Res. 2002;21:359-393.

  2. Boyle JE, Ghosh K, Gieser DK y cols., for the Dorzolamide-Timolol Study Group. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 1998;105(10):1945-1951.

  3. Janulevicienë I, Harris A, Kageman L y cols. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta Ophthalmol Scand. 2004;82:730-737.

  4. Konstas AG, Papapanos P, Tersis I, y cols. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus timolol and dorzolamide fixed combination. Ophthalmology. 2003;110 (7):1357-1360.

  5. Martinez A, Gonzalez F, Capeans C, y cols. Dorzolamide effect on ocular blood flow. Invest Ophthalmol Vis Sci. 1999;40(6):1270-1275.

  6. Harris A, Jonescu-Cuypers CP, Kagemann L, y cols. Effect of dorzolamide timolol combination versus timolol 0.5% on ocular blood flow in patients with primary open-angle glaucoma. Am J Ophthalmol. 2001;132:490-498.

  7. Harris A, Migliardi R, Rechtman E, y cols. Comparative analysis of the effects of dorzolamide and latanoprost on ocular hemodynamics in normal-tension glaucoma patients. Eur J Opthalmol. 2003;13(1):24-31.

  8. Ormrod D, McClellan K. Topical dorzolamide 2%/timolol 0.5%: A review of its use in the treatment of open-angle glaucoma. Drugs Aging. 2000;17(6):477-496.
 
PrintImprimir esta página
05-11-CST-2009-LAMT-1322113-W

† Marca registrada de Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co., Inc., Whitehouse Station, N.J., E.U.A.

Derechos reservados © 2003 Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co., Inc., Whitehouse Station, N.J., E.U.A
Privacy Policy Terms of Use Coyright © 1995-2007 Merck & CO